Loading clinical trials...
Loading clinical trials...
VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
Conditions
Interventions
VRC-ZKADNA085-00-VP
Locations
3
United States
Hope Clinic - Emory Vaccine Ctr
Decatur, Georgia, United States
University of Maryland Ctr. for Vaccine Development
Baltimore, Maryland, United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
August 2, 2016
Primary Completion Date
March 14, 2019
Completion Date
March 14, 2019
Last Updated
March 18, 2019
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions